Medicare beneficiaries with standalone Part D prescription drug plans should watch their 2027 premiums closely this fall after the Centers for Medicare & Medicaid Services said it will end a temporary premium stabilization demonstration at the close of 2026.
The short version: the drug benefit is not disappearing, but one federal cushion that helped limit standalone plan premium volatility is ending. CMS says final Medicare Advantage and Part D plan information, including average premiums, will be released in September before open enrollment.
That timing matters because the annual Medicare open enrollment period runs from October 15 through December 7. People who rely on a standalone drug plan will have a limited window to compare premiums, deductibles, covered drugs, pharmacy networks and alternatives for coverage that starts January 1, 2027.
What changed
CMS announced on July 28, 2026 that it will discontinue the Part D Premium Stabilization Demonstration at the end of calendar year 2026. The voluntary demonstration began in 2025 for standalone prescription drug plans after Inflation Reduction Act benefit changes shifted more drug-cost risk toward insurers.
The agency said Part D plan sponsors now have enough experience under the redesigned benefit to support their 2027 bids without the demonstration. CMS also released preliminary technical bid figures for 2027, including a national average monthly bid amount of $296.05 and a national base beneficiary premium of $41.33.
Those numbers do not tell a household exactly what it will pay. Part D premiums vary by plan, region, insurer and benefit design. The amount a person sees on a notice this fall can also be affected by whether they receive extra help, whether they switch plans, and whether they get drug coverage through Original Medicare with a separate Part D plan or through Medicare Advantage.
Why some premiums may rise
The demonstration was designed to smooth a transition. The 2025 redesign capped annual out-of-pocket drug spending for many Medicare beneficiaries and changed how costs are divided among enrollees, plans, drugmakers and the government. That created uncertainty for insurers setting standalone Part D premiums.
CMS says ending the demonstration returns the program to traditional market conditions. ABC News reported, citing an administration official, that the change is expected to raise premiums for about half of recipients. NPR reported that the subsidy reduced the average standalone drug-plan premium by $16 this year, citing KFF, and that exact 2027 effects will not be clear until CMS releases more plan information.
That uncertainty is the key consumer point. A higher base beneficiary premium does not automatically mean every person will see the same increase, and a low monthly premium does not automatically mean a plan is cheaper once deductibles, preferred pharmacies and covered medicines are counted.
What to check when prices arrive
Start with the annual notice of change from your current plan, then compare it against the official Medicare plan finder when 2027 options are available. Do not stop at the monthly premium. Check whether each regular prescription remains covered, whether it moved tiers, whether prior authorization or step therapy rules changed, and whether your preferred pharmacy remains in network.
People considering a Medicare Advantage plan because it includes drug coverage should compare the whole package, not just the drug premium. Medicare Advantage plans can have different provider networks, referral rules, out-of-pocket limits and drug formularies than Original Medicare paired with a standalone Part D plan.
For anyone taking expensive drugs, the most important comparison may be the full-year estimate, not the first monthly bill. Add premiums, deductible exposure, expected copays or coinsurance, pharmacy differences and the risk of a drug being restricted. A plan that looks cheaper in January can be more expensive over the year if it covers a key medication less favorably.
What is still unknown
The biggest unknown is plan-specific pricing. CMS said it will release the 2027 Medicare Advantage and Part D landscape in mid-to-late September after offerings are finalized. Until then, beneficiaries should treat broad premium estimates as planning signals rather than final bills.
It is also possible that some people will see little change, while others face a larger increase or a reason to switch plans. The practical move now is to gather a current medication list, note preferred pharmacies, watch for the September plan data, and set time during open enrollment to compare total annual costs before December 7.
This is general information, not personal insurance advice. People with complex drug needs, low-income subsidy questions or uncertainty about Medicare Advantage tradeoffs can contact Medicare, a State Health Insurance Assistance Program counselor, or a qualified benefits adviser before changing coverage.
